HHD

CMUH(Taiwan) Using AI to Monitor Home Hemodialysis

Retrieved on: 
Monday, March 18, 2024
Ultrafiltration, Blood pressure, Osmotic pressure, Chronic kidney disease, Renal replacement therapy, Patient, Peritoneal dialysis, Home hemodialysis, Fatigue, AI, Quality of life, Dehydration, Water, Safety, Dialysis, Patient safety, Family, HHD, Work, Medical device

TAICHUNG, March 18, 2024 /PRNewswire/ -- Chronic Kidney Disease has become a new "national disease" in Taiwan, and the number of patients requiring hemodialysis is increasing. Traditionally, hemodialysis patients and accompanies require at least an hour spent on commuting, and that maybe even more time consuming for those who live in suburbs. Moreover, patients almost feel tired or fatigue and need rest half a day following hemodialysis. Since 2019 in Taiwan, China Medical University Hospital (CMUH) has initiated and implemented AI monitoring system for hemodialysis patients. The unique AI system receives the messages sent by the dialysis machine to keep track of any risk message with incorporated AI system, ensuring patient safety and collecting information for prescription adaptation. Accredited with CMUH's AI technology, those who require hemodialysis are not necessary to visit a healthcare facility for this routine. Dr. Huey-Liang Kuo, Director of Hemodialysis Center at CMUH, stated that patients have been heathier and safer to do hemodialysis at home.

Key Points: 
  • Since 2019 in Taiwan, China Medical University Hospital (CMUH) has initiated and implemented AI monitoring system for hemodialysis patients.
  • The unique AI system receives the messages sent by the dialysis machine to keep track of any risk message with incorporated AI system, ensuring patient safety and collecting information for prescription adaptation.
  • Accredited with CMUH's AI technology, those who require hemodialysis are not necessary to visit a healthcare facility for this routine.
  • Dr. Huey-Liang Kuo, Director of Hemodialysis Center at CMUH, stated that patients have been heathier and safer to do hemodialysis at home.

Cytokinetics Presents Results From COURAGE-ALS at the 34th International Symposium on ALS/MND

Retrieved on: 
Thursday, December 7, 2023
Patient, Research and development, HHD, Caregiver, Hope, Weakness, Disease, Incidence, Muscle weakness, SAN, Edaravone, Clinical trial, University, Barrow Neurological Institute, FVC, COVID-19, Death, Data monitoring committee, Infection, Weather, Transport, Riluzole, Vital capacity, General Grievous, Cytokinetics, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the full results of COURAGE-ALS (Clinical Outcomes Using Reldesemtiv on ALSFRS-R in a Global Evaluation in ALS), were presented at the 34th International Symposium on ALS/MND by Jeremy Shefner, M.D., Ph.D., Lead Investigator of COURAGE-ALS, Professor of Neurology, Barrow Neurological Institute, University of Arizona College of Medicine Phoenix.

Key Points: 
  • At the second interim analysis the Data Monitoring Committee recommended the discontinuation of the clinical trial due to futility.
  • At the time of the discontinuation of COURAGE-ALS, 486 patients had started treatment with reldesemtiv or placebo and 276 had completed dosing through 24 weeks.
  • Patients treated with reldesemtiv declined 5.3 points per month (SD=5.3) while patients treated with placebo declined 4.8 points per month (SD=4.4).
  • The survey results showed that site personnel viewed remote visits favorably when considering whether to participate as a site in COURAGE-ALS.

New Data Insights Unveiled at ASN Kidney Week 2023 Point to the Impact of the Tablo® Hemodialysis System on Equitable Kidney Care

Retrieved on: 
Wednesday, November 1, 2023
Health, Medical Devices, Health Technology, Managed Care, General Health, Clinical Trials, Biotechnology, Patient, Medicare, Experiment (probability theory), Learnability, Medicine, HHD, MD, Nephrology, Research, Society, Dialysis, ASN, Abstract, Pythagorean Method of Memorization, Kidney, PRO, Insomnia, Health insurance, Pharmaceutical industry, Nursing, Medical device, Outset Contemporary Art Fund, Tablo

The five abstracts will be showcased at the American Society of Nephrology’s (ASN) Kidney Week 2023 in Philadelphia, PA, which runs November 2-5.

Key Points: 
  • The five abstracts will be showcased at the American Society of Nephrology’s (ASN) Kidney Week 2023 in Philadelphia, PA, which runs November 2-5.
  • The annual event gathers more than 10,000 kidney care professionals from across the globe, offering a forum to delve into the latest advancements in nephrology and to collaborate on kidney care innovation.
  • "The research abstracts we're presenting at ASN Kidney Week are more than data points; they are a testament to Tablo's adaptability, versatility and its profound impact on equitable healthcare,” said Michael Aragon, MD, Chief Medical Officer of Outset Medical.
  • Attendees are invited to visit the Outset booth (#1117) during the ASN meeting for more information.

Quanta™ to Present Highly Anticipated Real-World Evidence at the American Society of Nephrology (ASN) Kidney Week 2023

Retrieved on: 
Monday, October 30, 2023
Quanta, Global Medical Device Nomenclature, FDA, United Kingdom, FASN, Health care, University of Manitoba College of Medicine, Home, EST, HHD, Data, Safety, RN, FRCPC, Home run, Society, American Society of Nephrology, IDE, Dialysis, ASN, Doctor of Pharmacy, City, University, MHA, CCRP, TKT, MSN, Medical device, Medicine, Nephrology

BEVERLY, Mass., Oct. 30, 2023 /PRNewswire/ -- Quanta Dialysis Technologies, a medical technology company committed to making kidney care more accessible with its Quanta™ Dialysis System, today announced the presentation of real-world evidence from its Home Run™ study at the American Society of Nephrology (ASN) Kidney Week 2023, taking place November 2 – 5 in Philadelphia, Pennsylvania. 

Key Points: 
  • BEVERLY, Mass., Oct. 30, 2023 /PRNewswire/ -- Quanta Dialysis Technologies, a medical technology company committed to making kidney care more accessible with its Quanta™ Dialysis System, today announced the presentation of real-world evidence from its Home Run™ study at the American Society of Nephrology (ASN) Kidney Week 2023, taking place November 2 – 5 in Philadelphia, Pennsylvania.
  • The Quanta Dialysis System has been approved for use in the United Kingdom for home hemodialysis since 2020.
  • The commercial launch of the Quanta Dialysis System, powered by Trinal Kidney Therapy™ (TKT™) will also occur at ASN 2023.
  • Healthcare providers in attendance can stop by Quanta booth 937 to learn more about the Quanta Dialysis System, TKT, and future clinical studies.

Quanta Announces FDA 510(k) Submission for Home Use of Quanta Dialysis System

Retrieved on: 
Tuesday, September 19, 2023
CMS, Freedom, HHD, Centers for Medicare & Medicaid Services, Quality of life, Kidney disease, Dialysis, ASN, Medicare, American Society of Nephrology, Home, Patient, ESKD, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Food, Safety, Medical device, Pharmaceutical industry, Quanta

BEVERLY, Mass., Sept. 19, 2023 /PRNewswire/ -- Quanta Dialysis Technologies®, a medical technology company committed to making kidney care more accessible, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for indication expansion of the Quanta™ Dialysis System, a compact and easy-to-use hemodialysis device. The Quanta Dialysis System is currently indicated for use in chronic and acute care settings. The new submission seeks to expand use to include self-care, in-home hemodialysis.

Key Points: 
  • The Quanta Dialysis System is currently indicated for use in chronic and acute care settings.
  • "The Quanta Dialysis System is already providing patients in the U.K. with the freedom and flexibility that HHD offers.
  • This submission, pending regulatory clearance from the FDA, would make the Quanta Dialysis System the third device in the United States indicated for HHD in patients with end-stage kidney disease (ESKD).
  • Quanta's 510(k) submission is supported by clinical data from its Home Run™ study, a prospective, multi-center, open-label trial to assess the efficacy and safety of the Quanta Dialysis System for HHD.

Fresenius Medical Care Announces FDA Clearance of Versi®HD with GuideMe Software

Retrieved on: 
Wednesday, August 23, 2023
Fresenius Medical Care, Senior, HHD, Chronic kidney disease, Atmosphere, Frankfurt Stock Exchange, Connected health, COVID-19, All rights reserved, Dialysis, Patient, NxStage, Nursing, Nocturnality, Kidney, Water, FME, Bleeding, FMS, Health, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Environment, Food, Medical device

"We expect VersiHD with GuideMe Software to further simplify home hemodialysis for patients during training and at home," said Dr. Brigitte Schiller, Senior Vice President, Medical Officer, Home Therapies at Fresenius Medical Care.

Key Points: 
  • "We expect VersiHD with GuideMe Software to further simplify home hemodialysis for patients during training and at home," said Dr. Brigitte Schiller, Senior Vice President, Medical Officer, Home Therapies at Fresenius Medical Care.
  • VersiHD with GuideMe Software will support Fresenius Medical Care's mission of advancing access to home therapies to more patients."
  • Fresenius Medical Care, NxStage, the triangle logo, VersiHD, PureFlow and Nx2me are trademarks of Fresenius Medical Care Holdings, Inc. or its affiliated companies.
  • Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Hunting Hill Digital Launches with Investment from BaseLayer Ventures

Retrieved on: 
Wednesday, May 24, 2023
Technology, NFT, Finance, Banking, Other Technology, Professional Services, Digital Cash Management, Digital Assets, Small Business, Cryptocurrency, Asset Management, Hunting Hill, Entrepreneurship, Risk management, Guren, Ecosystem, Partnership, HHD, Clothes horse

Hunting Hill Digital (“HHD”), an innovative alternative asset manager exclusively focused on digital asset management services and strategies, has launched with an investment from BaseLayer Ventures, an early-stage venture capital firm helping entrepreneurs build businesses essential to the commercialization potential of digital assets and services.

Key Points: 
  • Hunting Hill Digital (“HHD”), an innovative alternative asset manager exclusively focused on digital asset management services and strategies, has launched with an investment from BaseLayer Ventures, an early-stage venture capital firm helping entrepreneurs build businesses essential to the commercialization potential of digital assets and services.
  • As an affiliate of Hunting Hill Global Capital ("HHGC"), HHD brings distinctive infrastructure and operational experience to the digital asset ecosystem.
  • HHD’s growth strategy includes exploration of opportunities in tokenization and NFT asset management, which align with BaseLayer Ventures’ investment mandate.
  • The partnership with BaseLayer Ventures also provides HHD access to a vast network of industry experts and advisors, as well as operational support, strategic guidance, and access to capital markets.

Outset Medical to Present Research Highlighting Home Hemodialysis Success for Underserved Populations at National Kidney Foundation Spring Clinical Meetings

Retrieved on: 
Wednesday, April 12, 2023
Health, Medical Devices, Health Technology, Other Health, Managed Care, Research, Science, Abstract, ESRD, Medicine, Medicaid, Female, Freedom, PD, HHD, Chronic kidney disease, Diabetes, Workplace, Advancing American Kidney Health, Woman, Mentorship, Kidney disease, Dialysis, Nursing care plan, Medicare, Peritoneal dialysis, MD, NKF, Patient, MA, National Kidney Foundation, Coronary artery disease, ESKD, Bias, CKD, Medical device, Health insurance, Nursing, Pharmaceutical industry, Outset Contemporary Art Fund, Nephrology

“Kidney disease is debilitating and takes away the freedom of choice for patients,” said Leslie Trigg, Chair and Chief Executive Officer of Outset.

Key Points: 
  • “Kidney disease is debilitating and takes away the freedom of choice for patients,” said Leslie Trigg, Chair and Chief Executive Officer of Outset.
  • This research solidifies that all patients deserve access to options such as home hemodialysis regardless of health disparities and environmental conditions.”
    The research will be presented at the National Kidney Foundation (NKF) Spring Clinical Meetings (SCM23) in Austin, TX, which run from April 11-15.
  • Kidney professionals from around the world will attend this event to learn about new developments in nephrology.
  • The abstracts can be read in their entirety on the Outset Medical clinical evidence page .

Outset Medical Awarded VA Contract Aimed at Improving Dialysis Care for Veterans

Retrieved on: 
Monday, August 15, 2022
Medical Devices, Veterans, Contracts, Health Technology, Telemedicine, Virtual Medicine, Managed Care, Health, General Health, Defense, FDA, U.S. Securities and Exchange Commission, Drug Quality and Security Act, Medicine, Dialysis, Forward-looking statement, SAC, Technology, Securities Exchange Act of 1934, Communication, Department, United States Department of Veterans Affairs, Patient, HHD, Form 10-K, Partnership, Water, Water purification, IHD, Risk, Kidney, Securities Act of 1933, SLED, Physician, IDIQ, Veteran, Solution, Annual report, Medical device, Outset Media

Outset Medical, Inc. (Nasdaq: OM) (Outset) announced today that the Strategic Acquisition Center (SAC) Office of Procurement, Department of Veterans Affairs awarded a national contract that enables the companys Tablo Hemodialysis System to be sold into the 106 VA hospitals in the U.S.

Key Points: 
  • Outset Medical, Inc. (Nasdaq: OM) (Outset) announced today that the Strategic Acquisition Center (SAC) Office of Procurement, Department of Veterans Affairs awarded a national contract that enables the companys Tablo Hemodialysis System to be sold into the 106 VA hospitals in the U.S.
    VA medical facilities across the U.S. provide dialysis care for 35,000 veterans.
  • Our honored veterans deserve to have the most advanced dialysis care possible, and it is our great privilege to support them through the SAC contract for hemodialysis care, said Leslie Trigg, Chair and Chief Executive Officer of Outset.
  • This partnership with the VA will further our mission to bring a technology-enabled, patient-centered approach to dialysis both in the acute and home setting.
  • Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis.

Outset Medical Presents New Data on Home Dialysis at National Kidney Foundation Spring Meetings

Retrieved on: 
Wednesday, April 6, 2022
Nursing, Medical Devices, Health, Other Health, Managed Care, Biotechnology, Hospital, Risk, National Kidney Foundation, HHD, Dialysis, 2022 NFL Draft, Nursing, Research, Social, PD, NKF, Nephrology, Patient, Medical device, Outset Media

Today, Outset Medical, Inc. (Nasdaq: OM) (Outset), a medical technology company reducing the cost and complexity of dialysis, announced the release of three new data sets related to home dialysis.

Key Points: 
  • Today, Outset Medical, Inc. (Nasdaq: OM) (Outset), a medical technology company reducing the cost and complexity of dialysis, announced the release of three new data sets related to home dialysis.
  • The scientific papers were presented during the 2022 National Kidney Foundation (NKF) Spring Clinical Meetings in Boston, Massachusetts, April 6-10.
  • The meetings bring together renal healthcare providers, including nephrologists, nurses, technicians, social workers, dietitians, and others in the space to learn more about the newest developments in advancing kidney care.
  • The three research papers can be read in their entirety on the Outset clinical evidence page or at the Outset booth (#804) during the NKF meeting.